DK0652966T3 - Fremgangsmåde til forøgelse af ekspression af virale proteiner - Google Patents
Fremgangsmåde til forøgelse af ekspression af virale proteinerInfo
- Publication number
- DK0652966T3 DK0652966T3 DK93918614T DK93918614T DK0652966T3 DK 0652966 T3 DK0652966 T3 DK 0652966T3 DK 93918614 T DK93918614 T DK 93918614T DK 93918614 T DK93918614 T DK 93918614T DK 0652966 T3 DK0652966 T3 DK 0652966T3
- Authority
- DK
- Denmark
- Prior art keywords
- viral proteins
- increasing expression
- proteins
- methods
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108010067390 Viral Proteins Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/921,807 US5474914A (en) | 1992-07-29 | 1992-07-29 | Method of producing secreted CMV glycoprotein H |
PCT/US1993/007299 WO1994003620A2 (en) | 1992-07-29 | 1993-07-29 | Method of increasing expression of viral proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0652966T3 true DK0652966T3 (da) | 2003-02-03 |
Family
ID=25446002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93918614T DK0652966T3 (da) | 1992-07-29 | 1993-07-29 | Fremgangsmåde til forøgelse af ekspression af virale proteiner |
Country Status (9)
Country | Link |
---|---|
US (2) | US5474914A (ja) |
EP (2) | EP1298215A3 (ja) |
JP (1) | JP3048387B2 (ja) |
AT (1) | ATE224956T1 (ja) |
AU (1) | AU680425B2 (ja) |
CA (1) | CA2140531C (ja) |
DE (1) | DE69332334T2 (ja) |
DK (1) | DK0652966T3 (ja) |
WO (1) | WO1994003620A2 (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242567B1 (en) * | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
US6162620A (en) * | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
US6855316B1 (en) * | 1994-02-14 | 2005-02-15 | University Of Hawaii | Baculovirus produced Plasmodium falciparum vaccine |
US5470719A (en) * | 1994-03-18 | 1995-11-28 | Meng; Shi-Yuan | Modified OmpA signal sequence for enhanced secretion of polypeptides |
MY114769A (en) * | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
US5807557A (en) * | 1994-07-25 | 1998-09-15 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex |
US6156319A (en) * | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
US5742181A (en) * | 1996-06-04 | 1998-04-21 | Hewlett-Packard Co. | FPGA with hierarchical interconnect structure and hyperlinks |
US6461814B1 (en) * | 1997-01-15 | 2002-10-08 | Dominic G. Spinella | Method of identifying gene transcription patterns |
JP2002533128A (ja) * | 1998-12-31 | 2002-10-08 | アドバンスド リサーチ アンド テクノロジー インスティテュート | アデノ随伴ウイルス2による感染のためのコレセプターとしてのヒト線維芽細胞増殖因子レセプター1 |
US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
US7108984B2 (en) * | 2000-01-12 | 2006-09-19 | Mount Sinai School Of Medicine | Methods of identifying modulators of the FGF receptor |
US20030100106A1 (en) * | 2000-02-08 | 2003-05-29 | Chang Sandra P. | Baculovirus produced Plasmodium falciparum vaccine |
US7015033B1 (en) * | 2000-05-25 | 2006-03-21 | Aventis Pasteur Limited | Co-expression of recombination proteins |
AU2002335709B8 (en) * | 2001-09-06 | 2008-12-18 | Cornell Research Foundation, Inc. | Human Immunodeficiency Virus Envelope Clycoprotein Mutants and Uses Thereof |
US20030199092A1 (en) * | 2002-01-11 | 2003-10-23 | The Regents Of The University Of California | Methods for increasing mRNA half-life in eukaryotic cells |
AU2002335710A1 (en) * | 2002-04-05 | 2003-10-27 | Progenics Pharmaceuticals, Inc. | Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods |
US7601491B2 (en) | 2003-02-06 | 2009-10-13 | Becton, Dickinson And Company | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
WO2006002079A2 (en) * | 2004-06-15 | 2006-01-05 | Progenics Pharmaceuticals, Inc. | Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex |
WO2006017724A1 (en) * | 2004-08-06 | 2006-02-16 | Becton, Dickinson And Company | Sequences and methods for detection of cytomegalovirus |
EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
CA2655934A1 (en) * | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
CA2667358A1 (en) * | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
DK3248610T3 (da) | 2009-05-05 | 2024-01-15 | Amgen Inc | Fgf21-mutanter og anvendelser deraf |
EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
WO2012006378A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery |
HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
CA2804492A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
PT4066856T (pt) | 2010-08-31 | 2023-01-02 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
CN103269713B (zh) | 2010-10-11 | 2016-01-20 | 诺华有限公司 | 抗原递送平台 |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
EP2502631A1 (en) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
AU2012322704B2 (en) | 2011-10-11 | 2017-09-07 | Novartis Ag | Recombinant self-replicating polycistronic RNA molecules |
CA2855818A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression |
WO2014005959A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Complexes of cytomegalovirus proteins |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN108300731A (zh) * | 2018-02-02 | 2018-07-20 | 暨南大学 | 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340740C (en) * | 1987-12-08 | 1999-09-14 | Eileen R. Mulvihill | Co-expression in eukaryotic cells |
DK0500686T3 (da) * | 1989-11-17 | 1996-06-10 | Upjohn Co | Antibakterielle tricycliske 6,5,5 / 6,6,5 kondenserede oxazolidinoner |
WO1992002628A1 (en) * | 1990-08-02 | 1992-02-20 | Chiron Corporation | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
EP0502179A1 (en) * | 1990-09-28 | 1992-09-09 | Smithkline Beecham Corporation | Enhanced expression of viral proteins in drosophila cells |
EP0509841A3 (en) * | 1991-04-18 | 1993-08-18 | Tonen Corporation | Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system |
NL9102009A (nl) * | 1991-11-29 | 1993-06-16 | Stichting Katholieke Univ | Produktie van bioactieve peptiden met recombinante cellen. |
-
1992
- 1992-07-29 US US07/921,807 patent/US5474914A/en not_active Expired - Lifetime
-
1993
- 1993-07-29 EP EP02078729A patent/EP1298215A3/en not_active Ceased
- 1993-07-29 AU AU48008/93A patent/AU680425B2/en not_active Expired - Fee Related
- 1993-07-29 JP JP6505519A patent/JP3048387B2/ja not_active Expired - Fee Related
- 1993-07-29 DK DK93918614T patent/DK0652966T3/da active
- 1993-07-29 DE DE69332334T patent/DE69332334T2/de not_active Expired - Lifetime
- 1993-07-29 WO PCT/US1993/007299 patent/WO1994003620A2/en active IP Right Grant
- 1993-07-29 EP EP93918614A patent/EP0652966B1/en not_active Expired - Lifetime
- 1993-07-29 AT AT93918614T patent/ATE224956T1/de active
- 1993-07-29 CA CA002140531A patent/CA2140531C/en not_active Expired - Lifetime
-
1995
- 1995-05-16 US US08/441,944 patent/US5767250A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1994003620A2 (en) | 1994-02-17 |
JP3048387B2 (ja) | 2000-06-05 |
CA2140531C (en) | 2000-03-28 |
EP0652966B1 (en) | 2002-09-25 |
EP1298215A3 (en) | 2007-09-26 |
DE69332334D1 (de) | 2002-10-31 |
JPH07509370A (ja) | 1995-10-19 |
CA2140531A1 (en) | 1994-02-17 |
WO1994003620A3 (en) | 1994-05-11 |
US5767250A (en) | 1998-06-16 |
DE69332334T2 (de) | 2003-08-07 |
ATE224956T1 (de) | 2002-10-15 |
AU680425B2 (en) | 1997-07-31 |
EP0652966A1 (en) | 1995-05-17 |
US5474914A (en) | 1995-12-12 |
EP1298215A2 (en) | 2003-04-02 |
AU4800893A (en) | 1994-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0652966T3 (da) | Fremgangsmåde til forøgelse af ekspression af virale proteiner | |
DE3382760D1 (de) | Herstellung von funktionellen menschlichen Urokinasepolypeptiden. | |
ATE177473T1 (de) | Herstellung von rekombinanten, menschlichem lactoferrin | |
DE3874798D1 (de) | Therapeutisches proteinagens in form von aerosol. | |
DK600688D0 (da) | Polypeptid, dets fremstilling og anvendelse | |
DK53497A (da) | Osteoinduktive præparater | |
DK0732340T3 (da) | Ekspression af porcine reproduktions- og respirationssyndromviruspolypeptider i den samme celle | |
DK0443874T3 (da) | Vektorer og forbindelser til ekspression af glycosyleringsmutanter af humanprotein C | |
DK169890A (da) | Kloning og ekspression af et protein, som modulerer det cellulaere respons paa type i interferon | |
FI882238A (fi) | Foerbaettringar i samband med organiska foereningar | |
DE68923496D1 (de) | Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression. | |
DK103891D0 (da) | Intralaesional behandling af pladeepitelcarcinoma med rekombinant human alfainterferon | |
DE3883596D1 (de) | Reinigung von rekombiniertem Hepatitis-B-Oberflächen-Antigen. | |
MX9400188A (es) | Metodo para producir en forma recombinante una proteina y complejo quecomprende dicha proteina. |